These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33060787)

  • 1. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
    Kopra K; Sharina I; Martin E; Härmä H
    Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of nitric oxide-cyclic GMP signalling in CNS cells and its possible regulation by cyclic GMP.
    Wykes V; Bellamy TC; Garthwaite J
    J Neurochem; 2002 Oct; 83(1):37-47. PubMed ID: 12358727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
    Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional and Unconventional Mechanisms for Soluble Guanylyl Cyclase Signaling.
    Gao Y
    J Cardiovasc Pharmacol; 2016 May; 67(5):367-72. PubMed ID: 26452163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems Pharmacology and Rational Polypharmacy: Nitric Oxide-Cyclic GMP Signaling Pathway as an Illustrative Example and Derivation of the General Case.
    Garmaroudi FS; Handy DE; Liu YY; Loscalzo J
    PLoS Comput Biol; 2016 Mar; 12(3):e1004822. PubMed ID: 26985825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
    Bellamy TC; Garthwaite J
    Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAY58-2667 Activates Different Soluble Guanylyl Cyclase Species by Distinct Mechanisms that Indicate Its Principal Target in Cells is the Heme-Free Soluble Guanylyl Cyclase-Heat Shock Protein 90 Complex.
    Dai Y; Stuehr DJ
    Mol Pharmacol; 2023 May; 103(5):286-296. PubMed ID: 36868790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
    Sandner P; Berger P; Zenzmaier C
    Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
    Sandner P
    Biol Chem; 2018 Jun; 399(7):679-690. PubMed ID: 29604206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
    Sandner P; Stasch JP
    Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
    Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Targeting of the Soluble Guanylate Cyclase.
    Makrynitsa GI; Zompra AA; Argyriou AI; Spyroulias GA; Topouzis S
    Curr Med Chem; 2019; 26(15):2730-2747. PubMed ID: 30621555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase.
    Golshiri K; Ataei Ataabadi E; Portilla Fernandez EC; Jan Danser AH; Roks AJM
    Basic Clin Pharmacol Toxicol; 2020 Aug; 127(2):67-80. PubMed ID: 31495057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease.
    Domek-Łopacińska KU; Strosznajder JB
    Mol Neurobiol; 2010 Jun; 41(2-3):129-37. PubMed ID: 20213343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
    Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G
    Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.
    Padovan-Neto FE; Sammut S; Chakroborty S; Dec AM; Threlfell S; Campbell PW; Mudrakola V; Harms JF; Schmidt CJ; West AR
    J Neurosci; 2015 Apr; 35(14):5781-91. PubMed ID: 25855188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
    Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
    Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.